Inspira Technologies Gets Israeli Approval for ART100 System
Ticker: IINNW · Form: 6-K · Filed: Jul 11, 2024 · CIK: 1837493
Sentiment: bullish
Topics: regulatory-approval, medical-device, israel
TL;DR
Inspira gets green light in Israel for ART100 respiratory device!
AI Summary
On July 11, 2024, Inspira Technologies Oxy B.H.N. Ltd. announced it received Israeli regulatory approval for its INSPIRA ART100 System. This approval is a significant step for the company's medical device, which aims to address respiratory failure.
Why It Matters
This regulatory milestone in Israel could pave the way for broader market access and adoption of Inspira's technology for treating respiratory failure.
Risk Assessment
Risk Level: medium — While regulatory approval is positive, the company's success will depend on market adoption, manufacturing scale-up, and further regulatory clearances in other key markets.
Key Players & Entities
- Inspira Technologies Oxy B.H.N. Ltd. (company) — The company that received regulatory approval.
- INSPIRA ART100 System (product) — The medical device that received approval.
- July 11, 2024 (date) — The date of the announcement and approval.
FAQ
What specific regulatory body granted approval for the INSPIRA ART100 System?
The filing states that the approval was granted by Israeli regulatory authorities.
What is the primary function of the INSPIRA ART100 System?
The INSPIRA ART100 System is designed to address respiratory failure.
When was the press release announcing this approval issued?
The press release was issued on July 11, 2024.
Is this the first regulatory approval for the INSPIRA ART100 System?
The filing does not explicitly state if this is the first approval, but it highlights it as a significant event.
What form was this report filed under?
This report was filed as a Form 6-K.
Filing Stats: 288 words · 1 min read · ~1 pages · Grade level 9.2 · Accepted 2024-07-11 08:45:13
Filing Documents
- ea0209273-6k_inspira.htm (6-K) — 11KB
- ea020927301ex99-1_inspira.htm (EX-99.1) — 12KB
- 0001213900-24-060637.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Inspira Technologies Oxy B.H.N. Ltd. Date: July 11, 2024 By: /s/ Dagi Ben-Noon Name: Dagi Ben-Noon Title: Chief Executive Officer 2